EVOX THERAPEUTICS LTD.

Company Overview

Evox Therapeutics, a spinout from Oxford University, is a biotechnology company that develops novel exosome-based biotherapeutics. Evox’s development pipeline is focused on inflammatory and immunologically driven diseases, neuroscience, and various rare diseases with significant unmet medical needs. Evox is backed by leading life sciences venture capital groups, including Borealis Ventures, Redmile, and OrbiMed, and is supported by a comprehensive intellectual property portfolio.

Evox aims to create the next generation of genetic medicines by advancing a pipeline of exosome-enabled gene therapies and genome editors. Evox’s technology platform is focused on engineering exosome proteins for the optimized loading of drug cargoes and targeting moieties into and onto exosomes. The company works on nucleic acid-based drugs, including antisense, siRNAs, and gene editing modalities. Evox has partnership deals with Takeda Pharmaceuticals and Eli Lilly and Co. to develop a pipeline of exosome technology-based therapeutics.

Company's Business Segments

• Exosome Therapeutics : The company helps improve the natural capabilities of exosomes and develop exosome-based therapeutics for treating rare diseases with minimal treatment options.